Fig. 3.

Genetic and pharmacological blockade of IL-1 prevents PNAC. a, c, d Peripheral serum concentrations of bilirubin, AST, ALT, and total bile acids in Il1r^−/−-treated, Casp1^−/−-treated, and Anakinra-treated DSS/PN mice relative to that in mice that were chow-fed, DSS/chow, or DSS/PN treated. *p < 0.05 vs. all other groups for WT mice, and ^#p < 0.05 knockout or Anakinra DSS/PN vs. DSS/PN wt; one-way ANOVA and Tukey's correction. b, f Liver mRNA for Abcb11 and Abcc2 in Anakinra-treated and in Il1r^−/−, DSS/PN mice relative to controls. *p < 0.05 DSS/PN vs. DSS/chow and chow, *p < 0.05 DSS/chow vs. chow; ^#p < 0.05 DSS/PN wt vs. DSS/PN Il1r^−/−; one-way ANOVA and Tukey's correction. e Peripheral serum concentrations of IL-1 receptor antagonist (Anakinra) in completely unmanipulated chow, Anakinra-treated DSS/PN, and Anakinra-treated DSS/NS (normal saline infused) mice. *p < 0.05 DSS/PN vs. chow, and ^#p < 0.05 DSS/PN vs. Anakina DSS/PN; one-way ANOVA and Tukey's correction